REG - ValiRx PLC - Issue of Share Options
06/09/2022 07:17
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220906:nRSF3496Ya&default-theme=true
RNS Number : 3496Y ValiRx PLC 06 September 2022
6 September 2022
ValiRx PLC ("ValiRx" or the "Company")
Issue of Share Options
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health announces today the grant
of share options under the Company share option scheme.
Further to the resolutions passed at the Annual General Meeting held on 30
June 2022, the Company has authority to issue up to 6,500,000 share options to
directors and members of staff and consultants.
2,850,000 share options have now been allocated to be issued to directors and
members of staff and consultants according to the schedule below, representing
a long-term incentive for those company members to perform to grow the Company
in alignment with shareholder expectations.
Details of 2,350,000 of the options issued are shown in the tables below.
Additionally, in lieu of consultancy fees and under a fixed term three year
contract for participation on the ValiRx Commercial Advisory Board, an
individual consultant has been awarded a singular benefit of 500,000 share
options, vesting immediately, with no additional restrictions at an exercise
price of 12p and expiring 6 September 2032.
The structure of the share options scheme was devised following feedback from
key shareholders following the Company's latest Annual General Meeting held on
30 June 2022.
No additional options are expected to be issued to the individuals set out
below prior to the 2023 Annual General Meeting, the remaining 3,650,000
authorised options are held in reserve for additional incoming directors,
staff members or consultants to the group.
The options detailed in the schedule below are exercisable only under market
conditions that demonstrate growth in the Company's market capitalisation.
Band 1 options vest only after the Company's share price has maintained a 20
Day VWAP (Volume Weight Average Price) of 25p, Band 2 options vest only after
the share price has maintained a 20 Day VWAP of 30p and Band 3 Options vest
only after the share price has maintained a 20 VWAP of 40p within 2 years of
the options being issued. If the price has not reached these price targets
by 6 September 2024, the options will lapse; if they meet the criteria, the
options can be exercised at any date to 6 September 2032 with an exercise
price of 12p.
Directors:
Band 1 Options Band 2 Options Band 3 Options
Suzanne Dilly - 300,000 300,000
Kevin Cox - 250,000 250,000
Gerry Desler - 100,000 100,000
Martin Lampshire - 75,000 75,000
Total - 725,000 725,000
Other Staff and Consultants:
Band 1 Options Band 2 Options Band 3 Options
Various consultants and staff (Total, including those to be awarded on 450,000 - 450,000
appointment)
The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com (http://www.valirx.com)
Dr Suzanne Dilly, CEO Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)
Dr Adam Hargreaves, Shareholder Representative Adam.Hargreaves@pathcelerate.com (mailto:Adam.Hargreaves@pathcelerate.com)
V Formation (Public Relations) +44 (0) 115 787 0206
www.vformation.biz (http://www.vformation.biz)
Lucy Wharton - Senior PR Executive
Sue Carr - Director lucy@vformation.biz
sue@vformation.biz
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0) 20 7213 088
Liam Murray/Jo Turner/Ludovico Lazzaretti
Cenkos Securities Limited (Joint Broker) Tel: +44 (0) 20 7397 8900
Russell Kerr/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate Finance)
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3657 0050
James Pope / Andy Thacker
Notes for Editors
About ValiRx
ValiRx accelerates the development of treatments in oncology and women's
health to improve patient lives. We provide the scientific, financial and
commercial framework towards enabling rapid translation of innovative science
into clinical development.
With our extensive and proven experience in research and drug development, we
select and incubate promising novel drug candidates and guide them through an
optimised process of development, from pre-clinical studies to clinic and
investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and commercial
domains, with the aim of achieving a more streamlined, less costly, drug
development process. We work closely with our selected collaborators and
leverage the combined expertise required for science to advance.
Lead candidates from our portfolio are out-licensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation. https://www.valirx.com/ (https://www.valirx.com/)
The Company listed on the AIM Market of the London Stock Exchange in October
2006 and trades under the ticker symbol: VAL.
Cautionary statement
Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name a) Suzanne Dilly
b) Kevin Cox
c) Gerry Desler
d) Martin Lampshire
2 Reason for notification
a. Position/Status a) Director
b) Director
c) Director
d) Director
b. Initial notification/ Initial notification
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name ValiRx PLC
b. LEI 213800VQKB9SJCQDET40
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary Shares
Identification Code
ISIN: GB00BLH13C52
b. Nature of the transaction Issue of Band 2 Options
c. Price(s) and volume(s)
Price(s) Volume(s)
a) 12p a) 300,000
b) 12p b) 250,000
c) 12p c) 100,000
d) 12p d) 75,000
d. Aggregated information
- Aggregated Volume N/A
- Price
e. Date of the transaction 06/09/2022
f. Place of the transaction London, UK
2
Reason for notification
a.
Position/Status
a) Director
b) Director
c) Director
d) Director
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a.
Name
ValiRx PLC
b.
LEI
213800VQKB9SJCQDET40
4
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification Code
Ordinary Shares
ISIN: GB00BLH13C52
b.
Nature of the transaction
Issue of Band 2 Options
c.
Price(s) and volume(s)
Price(s)
Volume(s)
a) 12p
b) 12p
c) 12p
d) 12p
a) 300,000
b) 250,000
c) 100,000
d) 75,000
d.
Aggregated information
- Aggregated Volume
- Price
N/A
e.
Date of the transaction
06/09/2022
f.
Place of the transaction
London, UK
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name a) Suzanne Dilly
b) Kevin Cox
c) Gerry Desler
d) Martin Lampshire
2 Reason for notification
a. Position/Status a) Director
b) Director
c) Director
d) Director
b. Initial notification/ Initial notification
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name ValiRx PLC
b. LEI 213800VQKB9SJCQDET40
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary Shares
Identification Code
ISIN: GB00BLH13C52
b. Nature of the transaction Issue of Band 3 Options
c. Price(s) and volume(s)
Price(s) Volume(s)
a) 12p a) 300,000
b) 12p b) 250,000
c) 12p c) 100,000
d) 12p d) 75,000
d. Aggregated information
- Aggregated Volume N/A
- Price
e. Date of the transaction 06/09/2022
f. Place of the transaction London, UK
2
Reason for notification
a.
Position/Status
a) Director
b) Director
c) Director
d) Director
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a.
Name
ValiRx PLC
b.
LEI
213800VQKB9SJCQDET40
4
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification Code
Ordinary Shares
ISIN: GB00BLH13C52
b.
Nature of the transaction
Issue of Band 3 Options
c.
Price(s) and volume(s)
Price(s)
Volume(s)
a) 12p
b) 12p
c) 12p
d) 12p
a) 300,000
b) 250,000
c) 100,000
d) 75,000
d.
Aggregated information
- Aggregated Volume
- Price
N/A
e.
Date of the transaction
06/09/2022
f.
Place of the transaction
London, UK
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IOEBKPBQKBKBOCKRecent news on ValiRx
See all newsREG - ValiRx PLC - Directorate Changes
AnnouncementREG - ValiRx PLC - Evaluation Agreement with Imperial College London
AnnouncementREG - ValiRx PLC - Board Re-structuring and update on requisition
AnnouncementREG - ValiRx PLC - Shareholder Requisition Notice
AnnouncementREG - ValiRx PLC - Proposed Appointment of Non-Executive Director
Announcement